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ABSTRACT  22 
Mitotane (o,p’DDD) is established in the adjuvant and advanced stage treatment of adrenocortical 23 
carcinoma and counteracts both tumour growth and tumour-related steroid production. Both the 24 
adrenal glands and the gonads are steroidogenically active organs and share a common embryogenic 25 
origin. Here we describe the effects of mitotane in two patients with metastatic Leydig cell tumour 26 
(LCT) of the testes and associated severe androgen excess (serum testosterone 93 and 88 nmol/l, 27 
respectively; male reference range 7-27 nmol/L). Both men suffered from severe restlessness, 28 
insomnia and irritability, which they described as intolerable and disrupting normal life activities. 29 
Urinary steroid profiling by gas chromatography-mass spectrometry (GC-MS) confirmed excess 30 
androgen production and revealed concurrent overproduction of glucocorticoids and glucocorticoid 31 
precursors, which under physiological conditions are produced only by the adrenal glands but not by 32 
the gonads. In a palliative approach, th y were commenced on mitotane, which achieved swift control 33 
of the hormone excess and the debilitating clinical symptoms, restoring normal quality of life. GC-MS 34 
demonstrated normalization of steroid production and decreased 5α-reductase activity, resulting in 35 
decreased androgen activation, and imaging demonstrated disease stabilization for 4-10 months. In 36 
conclusion, mitotane can be highly effective in controlling steroid excess in metastatic LCTs, with 37 
anti-tumour activity in some cases.   38 
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Testicular Leydig cell tumours (LCTs) are rare stromal tumours, comprising 1-3% of all 40 
testicular neoplasms (1, 2). LCTs result in precocious puberty in 10% of affected children due to 41 
excess androgen secretion (3). Affected adult men most commonly present with a painless testicular 42 
mass and significant androgen excess (4) and can also have tumour-related oestrogen excess, 43 
manifesting with gynecomastia in 10-30% of cases (4-6).  An estimated 10-15% of testicular LCTs 44 
are malignant (3, 7), although the true proportion remains debated (6, 8). The primary approach to 45 
malignant LCTs is surgical, usually involving orchidectomy, retroperitoneal lymph node dissection 46 
and lifelong surveillance (9). LCT metastases are rare and are detected on average 10 years after 47 
primary surgery (7), but therapeutic options are very limited, with no known role for radiotherapy and 48 
lack of efficacy of cytotoxic chemotherapy (7, 9). Therefore, prognosis for this rare endocrine cancer 49 
is poor, with an approximate median survival of two years (3, 4, 10).  50 
During human fetal development, gonads and adrenal glands both derive from the urogenital 51 
ridge and after separation they develop distinct steroidogenic features, with gonadal sex steroid 52 
production and adrenal production of glucocorticoids, mineralocorticoids and adrenal androgen 53 
precursors. Mitotane (o,p’DDD) is routinely used in the treatment of adrenocortical cancer, where it 54 
has been shown to control adrenal steroid excess and, to a degree, tumour proliferation (11). Mitotane 55 
also diminishes androgen action by inhibiting 5α-reductase (12) and hence activation of testosterone 56 
to 5α-dihydrotestosterone. Thus, we considered mitotane as a potentially useful drug in patients with 57 
metastatic Leydig cell tumour, in particular in patients with tumour-associated androgen excess.  Here 58 
we describe the effects of mitotane treatment in two patients with metastatic LCT, leading to a 59 
significant biochemical and clinical amelioration of the signs and symptoms of tumour-related steroid 60 
excess, and in one of them also to radiological stabilization of previously rapid disease progression.  61 
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Urinary steroid metabolome profiling at baseline and during mitotane treatment was carried 63 
out by gas chromatography-mass spectrometry, utilizing selected-ion-monitoring analysis for 64 
identification and quantification of 32 distinct steroid metabolites reflective of 24-h net steroid output, 65 
as previously described (13). Serum steroid measurements were carried out in the routine clinical 66 
biochemistry setting, using established and validated tandem mass spectrometry (androstenedione, 67 
testosterone) and immunoassays (DHEAS, 17β-oestradiol), respectively. 68 
We carried out immunohistochemistry for sterol-O-acyl transferase 1 (SOAT1) as described 69 
previously (14), using antibodies against SOAT1 (1:1000; ab39327; Abcam). The intensity of staining 70 
was scored as described by Sbiera et al (15).  71 
CASE REPORTS 72 
Case 1: A 51-year-old patient presented with severe restlessness, insomnia, impaired 73 
concentration, increased aggressiveness, redness of the face and body hair growth, all gradually 74 
developing over the last six months. Fifteen years previously, he had undergone an orchidectomy for 75 
LCT and thirteen years later excision of a retroperitoneal mass, confirmed on histology as LCT 76 
metastasis. Imaging revealed multiple lesions consistent with liver, lung and retroperitoneal 77 
metastases. Immunohistochemistry of a tissue biopsy confirmed vimentin positive, inhibin negative 78 
metastatic LCT. Serum testosterone was very high at 93nmol/L (normal male reference range 7-79 
27nmol/L). Urinary steroid profiling by gas chromatography-mass spectrometry (GC-MS) showed 80 
increased androgen metabolite excretion (sum of androsterone and etiocholanolone 101,476µg/24h; 81 
adult male reference range <8000µg/24h) as well as increased excretion of DHEA, metabolites of 82 
pregnenolone, progesterone, 17-hydroxypregnenolone, 17-hydroxyprogesterone, and cortisol (230 83 
µg/24h; normal <130) (Fig. 1A). Prognosis was assessed as poor and the patient declined 84 
chemotherapy. However, he agreed to the initiation of mitotane treatment in an attempt to improve the 85 
clinical signs and symptoms of tumour-related androgen excess that was significantly limiting his 86 
quality of life. Mitotane dose was gradually titrated to 3g per day, with concurrent hydrocortisone 87 
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replacement (20mg tid). Within a few weeks, androgen excretion decreased from 101,476 to 12,827 88 
µg/24h, with evidence of significant inhibition of 5α-reductase activity and normalization of other 89 
steroids that were increased at baseline (Table 1). Plasma mitotane concentrations considered 90 
therapeutic (anti-proliferative) in the context of adrenocortical carcinoma (14-20mg/L) (16) were 91 
reached after 5 months of treatment (Suppl. Table 1). Follow-up imaging still showed progressive 92 
disease at two months, but stable disease according to RECIST 1.1 criteria after six months of 93 
mitotane treatment (Suppl. Fig. 1). Alongside the decrease in androgens, the patient reported a 94 
significant improvement of his previously debilitating clinical signs and symptoms. He returned to 95 
full-time work and enjoyed good quality of life. After 10 months of mitotane treatment, he died 96 
suddenly of a suspected myocardial infarction; no post-mortem examination was carried out.  97 
Case 2: A previously fit-and-well 59-year-old man presented with a right testicular mass and 98 
underwent orchidectomy; histopathology revealed malignant LCT. Three years later he presented with 99 
lower back pain and imaging showed a large retroperitoneal mass, confirmed as disease recurrence by 100 
transcutaneous biopsy. He underwent laparoscopic removal of the mass together with retroperitoneal 101 
lymph node dissection. One year later, follow-up imaging revealed disseminated metastases, 102 
including liver, kidney and peritoneal deposits. He was unwell, with agitation, anxiety and insomnia. 103 
Biochemical work-up showed increased serum testosterone (88.5 nmol/L, normal 7-27), oestradiol 104 
(744 pmol/L, normal <156), androstenedione (7.0 nmol/L, normal 0.8-3.1), and DHEAS (> 27 105 
µmol/L, normal 0.91-6.76). GC-MS profiling showed increased steroid excretion including androgen 106 
metabolites (69,108 µg/24h, normal <8000) and cortisol (414 µg/24h, normal <130) (Fig. 1A). He 107 
rejected chemotherapy and agreed to palliative mitotane treatment with concurrent hydrocortisone 108 
replacement; mitotane was administered employing the high-dose saturation regimen (Day 1 500mg 109 
tds, Day 2 1000mg tds, and from day 3 onwards 1500 mg tds; therapeutic plasma mitotane levels 110 
were reached after 4 months (Suppl. Table 1). Mitotane decreased serum androgen production within 111 
four weeks. Six months after treatment initiation, plasma testosterone had decreased to 29.1 nmol/L 112 
and oestradiol to 177 pmol/L, while androstenedione and DHEAS had normalized. Urinary steroid 113 
profiling 4 months after initiation of miotane showed a decline in all previously raised steroid 114 
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metabolites and decreased 5α-reductase activity. This was paralleled by significant clinical 115 
improvement in signs and symptoms, specifically reduced restlessness, aggressiveness and insomnia. 116 
Imaging four months after initiation of mitotane revealed a mixed response, with regression of some 117 
previous lesions but emergence of new metastatic deposits in lung and abdomen. The patient passed 118 
away 12 months after his second recurrence, i.e. six months after the start of mitotane treatment.  119 
DISCUSSION 120 
Here we used mitotane, an established drug in adrenocortical carcinoma, in two patients with 121 
metastatic testicular LCT associated with severe androgen excess, clinically manifesting with severe 122 
restlessness, insomnia, irritability and impaired concentration. Both patients experienced significant 123 
improvement in signs and symptoms with mitotane therapy, swift normalization of steroid excess and 124 
some stabilization of radiologically quantified tumour load.  125 
In a comprehensive PubMed search (search terms: Leydig cell tumour, malignant Leydig cell 126 
tumour, metastatic Leydig cell tumour, mitotane, lysodren, and o,p’DDD) we identified eight cases of 127 
LCT treated with mitotane (Table 2). Four patients received mitotane as second- or third-line 128 
treatment for metastatic LCT for a very short time only (3 days to 8 weeks); none of them showed a 129 
biochemical, clinical or radiological response. The remaining four cases received mitotane as first-line 130 
treatment for metastatic LCT, with treatment duration varying between 10 weeks and 33 months 131 
(Table 2). All four patients experienced significant radiological tumour response and reduction in 132 
steroid excess during mitotane treatment. Azer and Braunstein (17) used mitotane to treat a patient 133 
with metastatic LCT for six months, resulting in a dramatic response with complete remission of 134 
multiple pulmonary metastases, which lasted three months prior to relapse. Radiological reduction in 135 
tumour load for several months was observed in two cases (18, 19). Abelson et al (20) noted a 136 
significant reduction in 17-ketosteroid excretion and clinical improvement in a metastatic LCT patient 137 
treated with mitotane for 18 months, while his disseminated metastases progressed. Adding the 138 
experience of our cases, mitotane can be considered a worthwhile palliative option in metastatic LCT, 139 
particularly when the disease is associated with steroid excess.  140 
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During human fetal development, adrenals and gonads both arise from the urogenital ridge 141 
and they both develop steroidogenic capacity, albeit with distinct features, i.e. sex steroid synthesis in 142 
the gonads and glucocorticoid, mineralocorticoid and androgen precursor synthesis in the adrenal 143 
glands. Benign testicular adrenal rest tumours, which are regularly found in men with congenital 144 
adrenal hyperplasia, have been shown to display features of both adrenal and gonadal steroidogenesis 145 
(21, 22). Using mass spectrometry, we observed that our two LCT patients showed not only androgen 146 
excess, but also increased production of glucocorticoid precursors and cortisol, without clinical signs 147 
of Cushing’s syndrome. Two previous case reports in patients with malignant LCTs have described 148 
ectopic production of steroids normally produced by the adrenal cortex, including cortisol and 149 
aldosterone (23, 24). In our two cases, both androgen excess and glucocorticoid overproduction 150 
responded well to mitotane treatment. Comprehensive steroid metabolome mapping by GC-MS has 151 
been used successfully to differentiate malignant from benign adrenocortical tumours (13). It will be 152 
useful to test in future studies whether steroid metabolome profiling would also help differentiate 153 
benign from malignant LCT and could have a role in follow-up monitoring.  154 
Recent studies have implicated sterol-A-acyl transferase 1 (SOAT1), previously also termed 155 
ACAT-1 for Acyl-coenzyme A cholesterol acyltransferases, as a target of mitotane action (14). 156 
SOAT1 is located in the endoplasmic reticulum and involved in intracellular esterification of free 157 
cholesterol. John Achermann’s group has shown that this enzyme operates downstream of SF-1 and is 158 
important for regulation of adrenal steroidogenesis (25). A recent study (14) has provided evidence of 159 
inhibition of SOAT1 by mitotane in an adrenocortical cell model, by demonstrating an increase in free 160 
cholesterol, oxysterols and fatty acids after treatment with mitotane. We had access to formalin-fixed 161 
paraffin-embedded tissue from the tumour recurrence in Patient 2 and used it for carrying out 162 
immunohistochemistry for SOAT1 (Fig. 1B), which demonstrated predominantly high and moderate 163 
expression, detected in 60% and 30% of the cells, respectively. Thus, it is likely that both the steroid-164 
ameliorating and anti-proliferative effects of mitotane are mediated by SOAT not only in 165 
adrenocortical carcinoma but also in LCT. 166 
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Based on our current findings, the use of mitotane in the palliative treatment of metastatic 167 
LCTs of the testes appears feasible and useful, with effective control of tumour-related steroid excess 168 
and possible beneficial effects on disease progression, a viable treatment option in a rare endocrine 169 
cancer that is not responsive to cytotoxic chemotherapy or radiotherapy. 170 
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Figure Legend 245 
Fig. 1:  246 
Panel A, Steroid synthesis in the two patients with metastatic testicular Leydig cell tumour as 247 
assessed by mass spectrometry-based 24-h urinary steroid profiling before initiation of mitotane 248 
treatment (log scale; closed circles, patient 1; open triangles, patient 2). Box plots represent medians 249 
and interquartile ranges from a group of 24 healthy male volunteers (age 40-60 years); whiskers 250 
represent the full range.  251 
Panel B, Immunohistochemical staining for Sterol-O-acyltransferaase 1 (SOAT1) using formalin-252 
fixed paraffin-embedded tissue from the recurrent tumour of patient 2, demonstrating high (60% of 253 
cells) to moderate (30% of cells) expression of SOAT1 in the tumour tissue. 254 
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Table 1: 24-h urine steroid metabolite excretion (µg/24h) in the two patients with metastatic Leydig Cell Tumour before (=baseline) and during mitotane treatment. 
The male reference range is derived from the 24-h urine steroid excretion observed in 24 healthy men aged 40-60 years. The numbers of the steroid metabolites relate to the 







healthy men  
(µg/24h) 





Month 1 Month 2 Month 4 Month 6 Month 9 Month 4 
Androgen and androgen precursor metabolites 
1 Androsterone 1,684 (477-5,915) 44,744 13,833 11,823 9,790 4,448 4,440 38,092 597 
2 Etiocholonaolone 1,668  (404-3,393) 56,732 30,283 37,617 22,408 9,798 8,387 31,016 2,697 
3 11β-hydroxy-androsterone 609 (131-2,302) 2,066 1,414 2318 301 169 174 13,351 643 
4 Dehydroepiandrosterone (DHEA) 202  (14-3,948) 1,939 1,034 434 294 194 311 47,344 359 
5 16α-hydroxy-DHEA 269 (0-1,492) 4,404 9,179 4,098 3,510 2,533 6,250 23,569 1,126 
6 5-pregnenetriol 181 (38-951) 1,558 2,574 2,484 2,600 1,575 2,483 20,891 1,053 
7 5-pregnenediol 326 (64-801) 19.972 27,844 24,732 25,548 9,545 15,450 168,192 11,304 
Mineralocorticoids and mineralocorticoid precursor metabolites 
8 
Tetrahydro-11-
deoxycorticosterone 94 (22-290) 445 195 162 188 29 128 308 22 
9 
5α-Tetrahydro-11-
deoxycorticosterone 107 (50-360) 62 100 87 52 32 49 74 18 
10 Tetraydrocorticosterone 97 (24-258) 300 154 263 169 41 105 177 18 
11 5α-Tetrahydrocorticosterone 193 (67-1,197) 130 261 489 0 0 0 90 0 
12 3α,5β-Tetrahydroaldosterone 30 (12-64) n.m. n.m. n.m. n.m. 13 28 293 25 
13 Tetrahydrodeoxycorticosterone 13 (5-36) n.m. n.m. n.m. n.m. 93 343 216 37 
Glucocorticoid precursor metabolites 
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14 Pregnanediol 157 (32-336) 3,249 1,857 1,474 1,171 455 646 4,832 199 
15 
3α,5α-17-hydroxy-
pregnanolone 14 (6-89) n.m. n.m. n.m. n.m. 13 18 809 8 
16 17-hydroxypregnanolone 133 (41-537) 7,163 1,940 1,589 1,538 817 998 39,306 551 
17 Pregnanetriol 576 (243-1,175) 9,562 5,701 4,295 4,366 2,128 2,677 28,349 1,495 
18 Pregnanetriolone 13 (5-58) 20 2 0 3 5 0 1,822 10 
19 Tetrahydro-11-deoxycortisol 61 (21-159) 594 525 690 492 314 911 116 322 
 
Glucocorticoid metabolites 
20 Cortisol 57 (22-224) 252 735 497 495 399 813 414 201 
21 6β-hydroxy-cortisol 114 (63-504) n.m. n.m. n.m. n.m. 7,657 23,193 393 3,578 
22 Tetrahydrocortisol 1,694 (772-4,534) 4,260 9,578 7,936 5,087 2,115 3,001 2,779 1,391 
23 5α-Tetrahydrocortisol 1,408 (229-6,744) 477 344 161 114 37 66 702 40 
24 α-cortol 319 (177-1,005) 1,665 2,566 1,880 1,256 524 831 597 286 
25 β-cortol 513 (255-1,678) 957 378 306 207 108 153 467 60 
26 11β-hydroxy-etiocholanolone 315 (23-899) 257 147 91 95 37 50 1092 89 
27 Cortisone 92.5 (39-348) 198 400 389 286 309 480 671 102 
28 Tetrahydrocortisone 3,333 (1,465-7,597) 3,978 2,391 2,113 1,564 763 1,124 5,597 807 
29 α-cortolone 1,228 (605-2,599) 3,892 2,661 2,222 1,166 410 539 1,623 479 
30 β-cortolone 696 (417-2,075) 1,110 300 303 216 108 213 1130 42 
31 11-oxo-etiocholanolone  464 (74-997) 1,059 734 736 868 844 1,196 3,144 267 
Total glucocorticoid metabolite 
excretion 
9,66 
(5,467-15,426) 16,789 19,353 15,807 10,391 4,773 7,220 13,980 3,408 
Steroid ratios indicative of 5α-
reductase:          
Androsterone/Etiochaolanolone 1.13 (0.05-3.00) 0.79 0.46 0.31 0.44 0.45 0.53 1.23 0.22 
5α-tetrahydrocortisol/tetrahydrocortisol 0.92 (0.05-2.27) 0.11 0.04 0.02 0.02 0.02 0.02 0.25 0.03 
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Table 1: Previously reported cases of patients with widespread metastases from testicular Leydig cell carcinoma treated with mitotane, presented in the order 


















Patient outcome Additional information whilst on 
mitotane therapy 
 













Died – no effect First-line radiotherapy (40000 rads 
cobalt therapy); 
Died 3 days after commencing 
mitotane therapy  
Grem et al., 
Cancer 1986 
(4) 









Survived another 5 years 
on alternative treatment 
(Lonidamine) 
First-line therapy cisplatin; 
mitotane stopped after 7 weeks due 
to abdominal discomfort and 
increasing nausea 










KS and 17-OHCS 
Died 8 weeks after 
commencing mitotane 
First line therapy 
cisplatin/vinblastin/bleomycin; 
Second line therapy 
cyclophosphamide/doxo-
rubicin/vincristine); 
Was concurrently on chemotherapy 
and radiotherapy. 
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Bertram et al., 
Cancer 1991 
(25) 





Normal 17-KS and 
17-OHCS; normal 
serum E1, E2, Aldo 










No response to mitotane 
 
First line treatment (treatment duration 10 weeks-33 months) 
 
Schwarzmann 
et al., 1989 
(15) 
59 10 weeks 9g/day 
(not done) 





Died 6 months after 
commencing mitotane 
therapy 
Reduction in abdominal tumor size 
and reduction in testosterone and 
estradiol to normal levels lasting 2 
months. Treatment stopped on 
patient’s wish following sudden 




1981 (14)  
















Died after deterioration 
and continuing metastatic 
spread of disease. 
Clinical improvement 
with mitotane 
Complete disappearance of 
pulmonary metastasis and clinical 
improvement after 14 weeks on 
mitotane. 3 months later pulmonary 
metastasis reappeared, mitotane was 
stopped and chemotherapy 
commenced. 
Abelson et al., 
Metabolism 
1966 (17) 













Died after clinical and 
biochemical 
improvement with 
mitotane but radiological 
progression  
Believed to be clinically improving, 
with reduction in urinary 17-
ketosteroids from 1462 to 100 
mg/day  
Van der Hem 
et al., J Urol 
1992 (16) 















17OHCS, An, Et, 
DHEA; normal 
serum T and 
DHEAS 
Died – metastatic disease 
stabilized for 18 months 
on mitotane treatment 
before disease slowly 
deteriorated 
decrease in retroperitoneal tumor, 
liver lesions, ascites along with 
stable disease for 18 months. Once 
disease deteriorated mitotane dose 
was escalated to 10g/day with no 
effect. 
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Suppl. Fig. 1: Computed tomography scans taken in Patient 1. A, Abdominal CT after two months of 
mitotane treatment showing metastatic Leydig cell tumor deposits, with heterogeneous omental masses 
and a large retroperitoneal mass. B, Abdominal CT after six months of mitotane treatment, demonstrating 
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Suppl. Table 1: Mitotane daily dose and plasma concentrations in the two Leydig cell tumor patients. 
Therapeutic range for plasma mitotane in adrenal cancer is accepted as 14-20 mg/L 

















1 1.5 4.0 4.5. n.m. 
2 3 5.9 4.5 9.1 
4 3 9.1 4.5 14.2 
5 3 23.5 4.5 n.m. 
6 2 17.6   
7 3 9.2   
 
n.m., not measured. 
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